Cardiotoxicity risk factors with immune checkpoint inhibitors

BACKGROUND: Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first described in murine models and, more recently, in numerous clinical case reports...

Descripción completa

Detalles Bibliográficos
Autores principales: Brumberger, Zachary L., Branch, Mary E., Klein, Max W, Seals, Austin, Shapiro, Michael D., Vasu, Sujethra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915459/
https://www.ncbi.nlm.nih.gov/pubmed/35277208
http://dx.doi.org/10.1186/s40959-022-00130-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915459/
https://www.ncbi.nlm.nih.gov/pubmed/35277208
http://dx.doi.org/10.1186/s40959-022-00130-5

Ejemplares similares